GALNT14 genotype as a response predictor for concurrent chemoradiotherapy in advanced esophageal squamous cell carcinoma
Metrics: PDF 1168 views | HTML 1882 views | ?
Yung-Kuan Tsou1, Kung-Hao Liang1,2,3, Wey-Ran Lin1,2,4, Hsien-Kun Chang5, Chen-Kan Tseng6, Chau-Ting Yeh1,2,3,4
1Department of Hepato-Gastroenterology, Chang Gung Memorial Hospital, Taoyuan, Taiwan
2Liver Research Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan
3Molecular Medicine Research Center, Chang Gung University, Taoyuan, Taiwan
4Chang Gung University, College of Medicine, Taoyuan, Taiwan
5Department of Oncology, Chang Gung Memorial Hospital, Taoyuan, Taiwan
6Department of Radiation Oncology, Chang Gung Memorial Hospital, Taoyuan, Taiwan
Kung-Hao Liang, email: firstname.lastname@example.org
Chau-Ting Yeh, email: email@example.com
Keywords: germline polymorphism, biomarker, cisplatin, gastrointestinal cancer, pharmacogenomics
Received: November 22, 2016 Accepted: February 20, 2017 Published: March 16, 2017
Esophageal squamous cell carcinoma is an aggressive cancer. We investigated genetic response predictors for patients with advanced esophageal squamous cell carcinoma receiving concurrent chemoradiotherapy. A cohort of 108 patients was recruited. Survival analysis showed that lower esophageal location of tumor, more advanced metastasis stage, and longer length of tumor were associated with poorer overall survival (adjusted P = 0.001, < 0.001, and 0.045, respectively), while the presence of complete/partial response to concurrent chemoradiotherapy was independently associated with better overall survival (adjusted P < 0.001). The GALNT14-rs9679162 “GG” genotype was associated with a lower rate of response (P = 0.014). Multivariate Cox-proportional hazards models also showed that the “GG” genotype was associated with a longer time to complete/partial response (adjusted P = 0.022), independent of leukocyte counts and gender. In conclusion, the presence of a complete/partial response to chemoradiotherapy was critical for advanced esophageal squamous cell carcinoma patients to achieve better overall survival. The GALNT14-rs9679162 “GG” genotype was associated with a longer time to complete/partial response of concurrent chemoradiotherapy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.